Dermatology patients on biologics and certain other systemic therapies should receive a “booster” messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations
- 23 August 2021
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 85 (5) , 1113-1116
Abstract
No abstract availableKeywords
Funding Information
- Eli Lilly and Company
- AbbVie
This publication has 4 references indexed in Scilit:
- Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory diseaseAnnals of the Rheumatic Diseases, 2021
- National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatmentsJournal of the American Academy of Dermatology, 2021
- Toward a COVID-19 vaccine strategy for patients with pemphigus on rituximabJournal of the American Academy of Dermatology, 2021
- Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies – A Danish population-based cohort studyJournal of Autoimmunity, 2021